Hematology Advisor Institute Spotlight Course

Medicine on the Move: Incorporating Novel JAK Inhibitors and Other Emerging Therapies into Higher-Risk Myelofibrosis Treatment

AMA PRA Category 1 Credit(s)^TM, ANCC Contact Hour(s), CE for Pharmacists

1.50 CME CE: Many patients with myelofibrosis are unresponsive or intolerant to ruxolitinib, learn about new JAK inhibitor therapies that provide options for these patients. Exp 2/24/24

Ring Sideroblast Quantification in Myelodysplastic Syndromes | myCME

AMA PRA Category 1 Credit(s)^TM

1.50 CME: Symposium on pathology of MDS-RS includes a cross-disciplinary interview enhanced by infographics and pathologist pocket guide. Exp 4/28/2023

BTK Inhibition in CLL: Interactive Self-Assessment | myCME

AMA PRA Category 1 Credit(s)^TM, CE for Pharmacists, ANCC Contact Hour(s), IPCE Credit(s)

0.75 CME CE: Bruton tyrosine kinase inhibitors are crucial in treating CLL. This interactive course reviews latest evidence and practice guidance. Exp 6/28/23

Complement Inhibition in Paroxysmal Nocturnal Hemoglobinuria | myCME

AMA PRA Category 1 Credit(s)^TM, CE for Pharmacists

1.00 CME CE: A lively expert discussion and real-world clinical case on PNH. Exp 6/30/23

The Role of Molecular Testing in CLL | myCME

AMA PRA Category 1 Credit(s)^TM, ANCC Contact Hour(s), CE for Pharmacists

0.25 CME CE: CLL is not one disease and its distinct heterogeneity means that some patients with CLL will not require treatment at all, while others require immediate aggressive treatment. Exp 9/30/2023

Maintenance Therapy and the Patient Voice in AML | myCME

AMA PRA Category 1 Credit(s)^TM, CE for Pharmacists, ANCC Contact Hour(s)

1.25 CME CE: Complex case-based scenarios managing patients with AML through induction, consolidation, transplant, and maintenance therapies. Exp 8/11/23

Management of Follicular Lymphoma | myCME

ANCC Contact Hour(s)

1.50 CE: Focuses on oncology nurse role in FL and discusses advances treatment, including updates to guidelines and two novel agents. Exp 4/29/23

Mitigating Veno-occlusive Disease Risk in R/R ALL | myCME

AMA PRA Category 1 Credit(s)^TM

0.50 CME: Veno-occlusive disease is a life-threatening condition. Early recognition and management are paramount to recovery. This activity is designed for the interdisciplinary care team. Exp 12/2/23

Targeting BCMA in Relapsed/Refractory Multiple Myeloma | myCME

AMA PRA Category 1 Credit(s)^TM, CE for Pharmacists, ANCC Contact Hour(s)

1.00 CME CE: Highlights benefits and risks of various BCMA-targeting strategies for patients with RRMM, including the side effects and toxicities. Exp 4/28/23

Meeting the Challenges of Treating Hemophilia | myCME

AMA PRA Category 1 Credit(s)^TM, ANCC Contact Hour(s)

1.00 CME CE: Faculty review MOA and clinical trial data for patients with hemophilia A and B and discuss how treatment approvals effect patients. Exp 7/29/23

Oncology Nurse: Caring for Relapsed or Refractory MM | myCME

ANCC Contact Hour(s), IPCE Credit(s)

0.50 CE: NP Beth Faiman discusses how to improve recognition and management of multiple myeloma. Exp 6/8/23

Optimizing Outcomes in Low-Risk MDS | myCME

ANCC Contact Hour(s), IPCE Credit(s)

1.00 CE: In-depth discussion for healthcare practitioners who manage patients with low-risk MDS so they can to better recognize the types of MDS. Exp 4/29/23

Caring for Patients with Relapsed or Refractory MM | myCME

ANCC Contact Hour(s), IPCE Credit(s)

1.00 CE: Cleveland Clinic’s Dr. Beth Faiman discusses MM treatment with the goal of keeping patients on therapy and maintaining their QOL. Exp 4/29/23